Emergent gets $23 million additional order for vaccine production

This post was originally published on this site

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca (NASDAQ:AZN) Plc’s COVID-19 vaccine bulk drug substance.

Add Comment